January 7, 2025 02:22 PM ESTUpdated 05:16 PM

Drugmakers cut some list prices, shrinking room for rebates in cancer, asthma and diabetes

Alexis Kramer

Pharma Editor

Bayer’s Nexavar and Boehringer Ingelheim’s Spiriva are among a handful of drugs with reduced US list prices for the new year, according to a Tuesday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Drugmakers cut some list prices, shrinking room for rebates in cancer, asthma and diabetes

Alexis Kramer

Pharma Editor

Sign up to read this article for free.

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Maze files for first biotech IPO of 2025, following $115M funding boost

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

Novo expands pact with Flagship's Valo to include obesity, diabetes for $190M near-term

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

Drug­mak­ers cut some list prices, shrink­ing room for re­bates in can­cer, asth­ma and di­a­betes

Alexis Kramer

Pharma Editor

Sign up to read this article for free.

more like this

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

No­vo ex­pands pact with Flag­ship's Va­lo to in­clude obe­si­ty, di­a­betes for $190M near-term

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

Drugmakers cut some list prices, shrinking room for rebates in cancer, asthma and diabetes

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Maze files for first biotech IPO of 2025, following $115M funding boost

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

Novo expands pact with Flagship's Valo to include obesity, diabetes for $190M near-term

ARCH, F-Prime and Mubadala pump $200M into former Denali programs